Clinical researchers have commenced recruitment of healthy volunteers in Seattle, the US, to take part in the first clinical trial of an experimental vaccine to fight coronavirus Covid-19.
This is considered to be a faster-than-expected start for the first vaccine prepared for testing, reported The Wall Street Journal.
Go deeper with GlobalData
On Wednesday, Kaiser Permanente Washington Health Research Institute stated that it intends to enroll 45 adults from the region in the study.
The volunteers will be in the ages between 18 and 55, from the Seattle-area and will enrolled over the course of 14 months.
The trial will test the safety of various doses of the vaccine, which is being developed by Moderna and to check if the doses produce the required immune response.
This trial is part one of three-phases to analyse the effectiveness of the vaccine, which uses a short segment of genetic code mRNA.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis genetic code can help stimulate an immune response and combat infection. The vaccine mRNA naturally breaks down without remaining in the body.
Volunteers are being urged to come to 11 in-person study visits and four phone visits during the 14-month period. These visits include one initial screening visit, two vaccination visits, and eight follow-ups.
The participants will receive two injections of the vaccine in the upper arm. They will be dosed 28 days apart. Doses given will be different to each group consisting of 15 people. The Group 1 will receive a dose of 25 micrograms (mcg), Group 2 100 mcg while Group 3 will be given a dose of 250 mcg.
